Zacks Investment Research
27 Jul 2026, 22:51 UTC · 1h ago
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
27 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Adma Biologics is currently assigned a Zacks Rank #5 (Strong Sell). — A 'Strong Sell' rating from a major research provider typically signals negative sentiment and potential price depreciation.
-0.70The consensus EPS projection for Adma Biologics has decreased by 2.03% over the last 30 days. — Downward revisions of earnings estimates usually indicate deteriorating short-term business trends.
-0.40Adma Biologics is expected to report a quarterly EPS of $0.16 and revenue of $125.77 million, representing growth of 6.67% and 3.11% respectively year-over-year. — Positive year-over-year growth in earnings and revenue is fundamentally bullish, though the magnitude here is modest.
+0.20Continue reading
6 related stories
Top 2 movers · tap to explore
Adma Biologics trades at a Forward P/E ratio of 10.3, significantly lower than the industry average of 19.59. — A lower P/E relative to the industry may suggest the stock is undervalued, though it can also reflect underlying risk.
Which stocks this story touches
The company is assigned a Zacks Rank #5 (Strong Sell) and has seen a decline in consensus EPS projections.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
